Frontier Biotechnologies Company Description

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health.

The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management.

It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include FB1002, an all-injectable long-acting HIV therapy; FB2001, a SARS-CoV-2 3CL protease inhibitor under clinical development for hospitalized patients as well as for post-exposure prophylaxis of Covid-19; FB3001, a new transdermal topical patch for musculoskeletal joint pain treatment under clinical development; and FB600, an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia.

The company was founded in 2013 and is headquartered in Nanjing, China.

Frontier Biotechnologies Inc.

Country	China
Founded	2013
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	395
CEO	Dong Xie

Contact Details

Address: Building E-2, Greenland Window Nanjing, 211199 China
Phone	86 25 6964 8375
Website	frontierbiotech.com

Stock Details

Ticker Symbol	688221
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
SIC Code	2836

Key Executives

Name	Position
Qi Shao	Senior Vice President, Chief Operating Officer and Chief Financial Officer
Dr. Rongjian Lu Ph.D.	Chief Technology Officer and Director
Yuting Zhu	Supervisor and Deputy GM Administrative Director
Hangzhou Lv	Senior Vice President of Marketing and Sales
Qianya Gao	Vice President, Deputy GM and Secretary of the Board of Directors
Dr. Dong Xie Ph.D.	Founder, Chairman, President and Chief Scientific Officer
Xin Guan	Accounting Supervisor
Dr. Changjin Wang Ph.D.	MD, CBO and Director
Michael Hu	C.M.O.
Michael Wang	Senior Vice President and Head of Infectious Diseases Therapy Area